Advancing Therapeutic Outlook for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment

 

What is Autosomal Dominant Polycystic Kidney Disease (ADPKD)?

The most common form of PKD is autosomal dominant polycystic kidney disease (ADPKD). The most frequent kidney illness passed down via families is ADPKD, which affects one in 400 to 1,000 people. The National Ambulatory Medical Care Survey (NAMCS), which was carried out by the National Center for Health Statistics (NCHS) and the Centers for Disease Control and Prevention (CDC) in the US, found that the diagnostic prevalence rate for ADPKD was 4.3 per 10,000.

Although there is a dearth of epidemiology information on ADPKD, most studies take the prevalence rate reported in previously published research studies. A dataset or epidemiological study that contains a sizable cohort of ADPKD diagnostic pools is desperately needed.

Since there is currently no viable cure for ADPKD, most efforts are directed around preventing complications, slowing cyst growth, and delaying the eventual progression to kidney failure. Since hypertension is the most prevalent complication associated with ADPKD and manifests early in the illness course, antihypertensive medications and diuretics have historically dominated the ADPKD therapeutic market. This multifactorial complication frequently causes left ventricular hypertrophy to develop, rapid renal function decline to ESRD, and cardiovascular mortality.

In addition to supportive therapies that restrict salt intake and boost water intake, it is critical to lower RAAS activation in hypertensive ADPKD patients. The suggested RAAS inhibitors for treating hypertension ADPKDs are ACEIs (enalapril, lisinopril, captopril, and others) or ARBs (valsartan, losartan, candesartan, olmesartan, and others). As a second-line ADPKD medication, beta-blockers and calcium channel blockers are administered to patients with uncontrolled hypertension despite receiving ACEI or ARB therapy. Additionally, these diuretics are utilized as the third line of ADPKD treatment with RAAS inhibitors and may successfully lower blood pressure in ADPKD patients. In hypertensive ADPKDs with normal kidney function, thiazide diuretics are the first choice, while long-acting loop diuretics are the primary choice for those with impaired kidney function.

The market for treating ADPKD saw a significant shift in 2018 with the recent approval of Otsuka Pharmaceuticals' Jynarque (tolvaptan), a V2 receptor antagonist. This was especially true of the late-stage treatment market. A medicine that had already received clearance in the EU (2015) and Japan's market for ADPKD received a much-needed boost from the US approval (2014). Even though it is only approved for late-stage, fast-advancing ADPKD, its monopoly and declared Orphan Drug Exclusivity prevent generic pharmaceuticals from entering the market for ADPKD treatments, making it the market leader in PKD medications. The prevalence of the disease is growing, and people are becoming more aware of it, helped by advantageous reimbursement policies like the BridgeRx program or the Otsuka Patient Assistance Foundation (OPAF).

A few more interesting therapeutic approaches for treating ADPKD have also been identified in animal models, based on the roles of intracellular calcium, cell cycle regulation, MAPK pathway, epigenetic DNA, interstitial inflammation, and cell therapy. Studies on cultured cells, such as AT-20494 (Janssen Pharmaceuticals) and RGLS8429, are just beginning (Regulus Therapeutics). Bosutinib (Pfizer), Venglustat (Sanofi), and Lixivaptan (Centessa), among other promising indicated medicines in the ADPKD pipeline that was in the late stages of trials, were stopped because they either did not fulfill their primary endpoint or had subpar safety and effectiveness profiles. One should resist becoming overly enthusiastic until the medicine enters the ADPKD treatment market because of the complex nature of illness progression, which creates challenges in converting scientific breakthroughs into reality.

Our study shows that the primary unmet need in ADPKD care is that the existing ADPKD treatment merely tries to delay the illness development rather than entirely curing it. The current ADPKD therapy choices either control late-stage ADPKD patients' declining kidney function or treat associated problems such high blood pressure, hematuria, renal discomfort, and infections. In the upcoming years, progress in the field of research and development will aid in the anticipated launch of promising medicines in the ADPKD pipeline, such as Bardoxolone methyl, XRx-008, and Tesevatinib.

Related Reports: 

Diagnostic Imaging Equipment Market

 

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

 

Invasive Candidiasis Market

 

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.

 

Sialidosis Market 

 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Filgrastim Biosimilar Insight

 

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Pain Management Devices Market

 

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services